A5025794705- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- Bacterial Identification and Susceptibility Testing
- Nutrition and Health in Aging
- Nail Diseases and Treatments
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Body Composition Measurement Techniques
- Glioma Diagnosis and Treatment
Institut Català d'Oncologia
2016-2025
Institut d'Investigació Biomédica de Bellvitge
2015-2025
Duran i Reynals Hospital
2015-2024
Ajuntament de L’Hospitalet
2013-2024
Universitat de Barcelona
2012-2023
Centro de Investigación Biomédica en Red
2023
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2023
Instituto de Salud Carlos III
2023
Bellvitge University Hospital
2005-2021
Regeneron (United States)
2019
Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab monotherapy followed by plus doxorubicin, vinblastine, dacarbazine (N-AVD) for newly diagnosed cHL.Patients 18 years age or older with untreated, advanced-stage (defined as III to IV IIB unfavorable risk factors) cHL were eligible this multicenter,...
For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus (A+CHP) exhibited statistically superior progression-free survival (PFS) per independent central review improvements in overall versus CHOP for the of systemic anaplastic large cell other CD30-positive PTCL.
Abstract Background We aimed to describe the current rates of inappropriate empirical antibiotic treatment (IEAT) in oncohematological patients with febrile neutropenia (FN) and its impact on mortality. Methods This was a multicenter prospective study all episodes bloodstream infection (BSI) high-risk FN (2006–2017). Episodes receiving IEAT were compared appropriate therapy. Adherence Infectious Diseases Society America (IDSA) recommendations evaluated. Multivariate analysis performed...
In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve results before autologous stem-cell transplantation (ASCT).
The frequency of gastrointestinal (GI) tract involvement in mantle cell lymphoma (MCL) at diagnosis is reported to be below 30%. To investigate the actual GI by MCL, upper and lower endoscopy was prospectively performed on 13 untreated MCL patients diagnosis. Multiple biopsies from endoscopically normal abnormal gastric colonic mucosa were studied with immunohistochemistry (IHC) for CD20, CD5, cyclin D1, as well fluorescence situ hybridization (FISH) t(11;14) polymerase chain reaction (PCR)...
The elective treatment of patients with post-transplant lymphoproliferative disorders is controversial. purpose this trial was to evaluate the efficacy extended doses rituximab adapted response in after solid organ transplantation.This a prospective, multicenter, phase II trial. Patients were treated reduction immunosuppression and four weekly infusions rituximab. Those who did not achieve complete remission (CR) received second course infusions. primary end-point study CR rate.Thirty-eight...
Summary This international retrospective study of 593 S plenic M arginal Z one L ymphoma ( SMZL ) patients aimed to identify factors that determine treatment initiation and influence lymphoma‐specific survival LSS ). Logistic regression was used the associated with treatment. A Cox analyse in a derivation cohort 366 patients. produced prognostic index PI enabled identification three risk groups. The resulting stratification validated another 227 compared Interguppo Italiano Linfomi IIL score...
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority which have high relapse rates following standard therapy. Despite use consolidative stem cell transplant (SCT) frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall with brentuximab vedotin plus cyclophosphamide,...
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients SMZL that eventually underwent large B-cell transformation. Tumor material was obtained either only at diagnosis (9 patients), and (18 (14 patients). Samples were categorized in 2 groups: (1) (SMZL, n = 27 samples), (2) (SMZL-T, 32 samples). Using copy number arrays a next-generation sequencing custom panel, we identified the main genomic alterations SMZL-T...
Abstract Background and purpose A real‐time biomarker in chemotherapy‐induced peripheral neurotoxicity (CIPN) would be useful for clinical decision‐making during treatment. Neurofilament light chain (NfL) can detected blood the case of neuroaxonal damage. The aim study was to compare levels plasma NfL (pNfL) according type chemotherapeutic agent severity CIPN. Methods This single‐center prospective observational longitudinal included patients treated with paclitaxel (TX; n = 34), brentuximab...
Currently, there are no consensus guidelines regarding the best therapeutic option for patients with extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) type.Patients systemically untreated or de novo MALT lymphoma received rituximab 375 mg/m(2) intravenously on Day 1 and fludarabine 25 Days through 5 (Days 1-3 in aged >70 years) every 4 weeks, to 6 cycles. After first cycle, oral could be given orally at 40 same schedule. 3 cycles, a workup was done. Patients who...